Legendary singer Etta James succumbs to leukemia

According to multiple media outlets, legendary jazz singer Etta James has died at the age of 73 due to complications from leukemia.

During her long and illustrious career, James was awarded six Grammys and was inducted into the Rock n Roll Hall of Fame. She was the unforgettable voice behind such classics as "The Wallflower" and "At Last," the latter of which was highlighted most recently by the runner-up in Simon Cowell's U.S. version of 'The X Factor,' Josh Krajcik.

James was born Jamesetta Hawkins in Los Angeles in 1938 to a teen mother. She never knew her father but long suspected that it was billiards legend Minnesota Fats. She got her start after being discovered singing in church and became something of a gospel prodigy, though her incredible career spanned several genres and even today remains difficult to pin down.

She was diagnosed with a chronic form of leukemia in 2010 but also had co-morbid conditions, including kidney failure, dementia and hepatitis C.

photo by Roland Godefroy

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap